

Addendum to Recce Signs Middle East Licensing Term Sheet

Sydney Australia, 27 May 2026: Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**), (**Recce or the Company**), a leading developer of synthetic anti-infectives, refers to its announcement titled 'Recce Signs Middle East Licensing Term Sheet' released on 27 May 2026 (**the Announcement**) regarding entry into a non-binding term sheet with a leading Middle Eastern pharmaceutical company for a proposed 10-year exclusive licensing arrangement. This document should be read together with the Announcement.

The Company confirms:

1. that it does not consider the identity of the counterparty to be information that a reasonable person would expect to have a material effect on the price or value of the Company's securities;
2. that the Announcement contains all material information relevant to assessing the impact of the contract on the price or value of the Company's securities, and is not misleading by omission; and
3. the Announcement describes the counterparty as a leading publicly listed Middle Eastern pharmaceutical company with a multi-billion-dollar market capitalisation and a distribution network spanning over 30 international markets. As a major listed company, the counterparty's financial reports are publicly available and independently audited. The Company reviewed these reports as part of its standard commercial due diligence, which confirmed the counterparty's financial capacity to fulfil all payment obligations should the parties execute a definitive agreement following this non-binding term sheet.

This announcement has been approved for release by Recce Pharmaceuticals Board.



About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

Media and Investor Relations

Chief Executive Officer

James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Australia

Andrew Geddes
Seed Media
andrew@seedmedia.com.au

USA & Europe

Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com